Terray Therapeutics adds Dr. Sudha Parasuraman to its Board as Independent Director

– USA, CA –  Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale, today announced the appointment of Dr. Sudha Parasuraman (MD) to its Board as an Independent Director.

About Dr. Sudha Parasuraman

Dr. Parasuraman is an accomplished biopharmaceutical executive who brings more than 20 years of clinical development, operations, and business experience in immunology, inflammation, oncology, hematology, and rare diseases. She is currently the Chief Medical Officer at Ribon Therapeutics leading the clinical strategy and development of novel, first-in-class therapeutics targeting the stress response pathways in oncology and Inflammatory diseases. Before joining Ribbon in 2019, she was the Chief Medical Officer at X4 Pharmaceuticals, leading their immuno-oncology and rare disease programs. Dr. Parasuraman previously held leadership positions at uniQure Inc, Novartis, and Millennium/Takeda and played a pivotal role in the successful approvals of subcutaneous VELCADE (bortezomib), KISQALI (ribociclib), and HEMGENIX (etranacogene dezaparvovec-drlb). Before joining the industry, Dr. Parasuraman was a faculty member at Harvard Medical School and a staff physician at Children’s Hospital of Boston, Dana Farber Cancer Institute, and Brigham and Women’s Hospital. She received her medical degree from the University of Madras, India, completed her pediatric residencies at Children’s Hospital of Michigan and Los Angeles County/University of Southern California Medical Center, and fellowship in pediatric hematology-oncology at St. Jude Children’s Research Hospital in Memphis, TN.

About Terray Therapeutics

Terray Therapeutics is a biotechnology company operating at the convergence of AI, biology, medicinal chemistry, automation, and nanotechnology to propel drug discovery into the information age. Terray’s proprietary integrated computational and experimental platforms generate massively scaled, powerfully agnostic chemical data that are purpose-built to power computational learning and reveal new interactions. This foundation is building an iterative, flexible chemistry engine that delivers more precise therapies to patients faster than ever before.

For more information: https://terraytx.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.